Sector Gamma AS Trims Stock Position in QIAGEN N.V. $QGEN

Key Points

• Sector Gamma AS reduced its holdings in Qiagen N.V. by 8.3%, now owning 187,000 shares which represent approximately 2.4% of its total holdings.
• Qiagen recently reported $0.60 EPS for the quarter, meeting the consensus estimate, with revenue increasing by 7.7% year-over-year to $533.54 million.
• A number of analysts have updated their price targets for Qiagen, with UBS raising its target from $48 to $50 and Bank of America increasing it from $50 to $53, reflecting varied investor sentiment.

Sector Gamma AS lowered its holdings in QIAGEN N.V. (NYSE:QGEN - Free Report) by 8.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 187,000 shares of the company's stock after selling 16,993 shares during the period. QIAGEN makes up 2.4% of Sector Gamma AS's holdings, making the stock its 19th biggest holding. Sector Gamma AS owned approximately 0.08% of QIAGEN worth $7,508,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Neuberger Berman Group LLC boosted its stake in shares of QIAGEN by 102.4% in the 1st quarter. Neuberger Berman Group LLC now owns 19,352 shares of the company's stock valued at $767,000 after buying an additional 9,791 shares during the period. Prudential PLC boosted its stake in shares of QIAGEN by 132.5% in the 1st quarter. Prudential PLC now owns 47,166 shares of the company's stock valued at $1,862,000 after buying an additional 26,880 shares during the period. Public Sector Pension Investment Board boosted its stake in shares of QIAGEN by 5.2% in the 1st quarter. Public Sector Pension Investment Board now owns 113,046 shares of the company's stock valued at $4,478,000 after buying an additional 5,593 shares during the period. Nuveen LLC purchased a new position in shares of QIAGEN in the 1st quarter valued at about $44,078,000. Finally, Invesco Ltd. boosted its stake in shares of QIAGEN by 13.5% in the 1st quarter. Invesco Ltd. now owns 449,638 shares of the company's stock valued at $18,053,000 after buying an additional 53,383 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen cut QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. UBS Group lifted their price objective on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Bank of America raised their price target on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Cowen restated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Finally, Barclays assumed coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, QIAGEN currently has a consensus rating of "Hold" and an average price target of $49.69.

QIAGEN Stock Up 0.1%

Shares of NYSE QGEN traded up $0.0280 during mid-day trading on Wednesday, reaching $49.2180. The company had a trading volume of 1,139,837 shares, compared to its average volume of 1,436,019. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm has a 50 day simple moving average of $48.53 and a two-hundred day simple moving average of $43.81. The stock has a market cap of $10.94 billion, a P/E ratio of 29.08, a PEG ratio of 2.58 and a beta of 0.64. QIAGEN N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company's revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts predict that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Announces Dividend

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a $0.25 dividend. This represents a dividend yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is presently 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.